← Back to Search

Other

HMPL-760 for Mantle Cell Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Hutchison Medipharma Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 1st dose of study drug to the time of progressive disease, assessed up to 36 months
Awards & highlights

Summary

This trial is testing a new drug, HMPL-760, on patients who have already been treated for a type of cancer called CLL/SLL or NHL. They're testing how safe and tolerable the drug is, as well as its efficacy.

Eligible Conditions
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Lymphoplasmacytic Lymphoma
  • Richter Syndrome
  • Waldenstrom Macroglobulinemia
  • Non-Hodgkin's Lymphoma
  • Medial Collateral Ligament

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 1st dose of study drug to the time of progressive disease, assessed up to 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 1st dose of study drug to the time of progressive disease, assessed up to 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of AEs/SAEs
Incidence of DLTs
MTD
+1 more
Secondary outcome measures
Chemokines
Clinical Benefit Rate (CBR)
Duration of Response (DoR)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
All patients to receive HMPL-760 daily.

Find a Location

Who is running the clinical trial?

Hutchison Medipharma LimitedLead Sponsor
101 Previous Clinical Trials
13,599 Total Patients Enrolled
HutchmedLead Sponsor
30 Previous Clinical Trials
5,796 Total Patients Enrolled
Vijay Jayaprakash, MBBS, PHDStudy DirectorHutchison Medipharma Limited
1 Previous Clinical Trials
75 Total Patients Enrolled
~0 spots leftby Jul 2025